Cantor Fitzgerald lowers Zscaler stock price target to $225 on FY27 outlook

Zscaler beat fiscal Q3 2026 estimates on revenue, ARR, and EPS and raised full-year revenue guidance, but lowered free cash flow outlook due to higher capex and gave a conservative initial fiscal 2027 framework of 16% to 17% revenue growth. Shares fell more than 20% this week as investors focused on softer fourth-quarter guidance, sales-leadership turnover, and slower Red Canary ARR assumptions. Analysts remained mixed, with price targets ranging from $175 to $230 and Cantor Fitzgerald trimming its target to $225 while keeping an Overweight rating.

Analysis

The market is pricing ZS as a guidance-quality story, not a quarterly execution story. That matters because the base business is still compounding above the market, but the multiple is now being anchored to the slower of two growth engines: new-logo acquisition and the SecOps attach cycle. The real second-order issue is that management’s pull-forward of data-center capex signals a willingness to sacrifice near-term free cash flow to preserve supply optionality, which is usually rational but tends to compress valuation when investors are already de-rating growth durability.

The more important competitive read-through is that platform consolidation is winning, but only if the vendor can prove cross-sell efficiency. If integrated SecOps adoption stalls inside the installed base, the company risks being seen as a large-ACV replacement vendor rather than a net-new expansion platform, which would tighten sales efficiency assumptions across the cyber cohort. That is a problem for peers with similar “land-and-expand” narratives because the market will likely demand clearer proof of attach, not just ARR scale.

Near term, the stock can stay weak for days to weeks because the next catalyst is not another beat; it is evidence that the fiscal 2027 framework was intentionally conservative. The reversal setup comes over the next one to two quarters if new leadership stabilizes the go-to-market motion and incremental RPO conversion remains intact. If billings or remaining performance obligations decelerate meaningfully, the current drawdown likely proves to be only the first leg of a longer multiple reset.

The contrarian view is that the selloff may already be discounting the exact issues management is trying to de-risk. A 20%+ correction after an earnings beat often embeds an overly linear read on sales-leader turnover, when in practice the larger driver may simply be a tougher budget environment and a transition toward more efficient enterprise sell-through. If the company can show that the capex spike was a one-time procurement hedge and not a structural margin reset, the market could re-rate the stock quickly back toward a premium multiple.

Key Decisions for Investors

• Short ZS into any relief rally over the next 1-3 weeks; risk/reward favors selling strength until management proves fiscal 2027 growth re-acceleration. Use a tight stop above the pre-earnings gap level because a stabilization narrative could trigger a sharp bounce.
• Pair trade: long CRWD / short ZS for 1-2 quarters. The thesis is that the market will reward clearer multi-product operating leverage and penalize any execution ambiguity around SecOps attach and sales transition.
• If already long cybersecurity, rotate exposure from ZS into the more visible grower names for the next 60-90 days. This is a relative-value de-risking trade rather than a sector call.
• For event-driven investors, consider a bearish put spread on ZS expiring after the next quarterly print. The trade monetizes the chance that the current framework gets revised lower before sentiment can repair.
• Watch for a reversal cue: if quarterly net new ARR and RPO stabilize while FCF normalizes after the capex step-up, cover shorts quickly; the stock can retrace a meaningful portion of the drawdown in one reporting cycle.